EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 40 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ibrutinib ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce MOST POPULAR Phytochemicals and Antioxidants December 11, 2020 Marshall University Study Finds That Walnuts Suppress Breast Cancer Growth And... April 16, 2019 Triple negative breast cancer drug given initial ‘no’ for NHS in... April 8, 2022 Liquid Biopsies on the Horizon for Children with Solid Cancers April 11, 2023 Load more HOT NEWS Four randomized prospective degree compared 90 days regarding neoadjuvant ADT observed... FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... ACS’s Updated Cervical Cancer Screening Guidelines Explained Women Diagnosed with Early Breast Cancer Since 2000 Have About a...
